Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

VTLi Nurse Patient Results screen

Clinical Evidence:
Atellica® VTLi Patient-side Immunoassay Analyzer
Articles in Scientific Publications

Read articles

Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h
Authors: Cullen L., Apple F., et. al.
2024 Study Published in the European Heart Journal

New international multicenter study showcasing the impact of the Atellica® VTLi high-sensitivity troponin I (hs-cTnI) assay in the emergency assessment of patients with suspected acute myocardial infarction (AMI).

What percentage (range) of suspected ACS patients could be assessed “low risk” based on VTLi hs-cTnI test results per the recent publication in European Heart Journal by Cullen L. et al?


0%

Determination of a wholeblood single-test low-risk threshold for a point-of-care high-sensitivity troponin assay
Authors: Pickering J., Than M., et.al.
2024 Study Published in the Emergency Medicine Journal

To enhance care delivery in emergency departments (EDs) through faster risk-stratification methods, this study showcases initial findings from the ICare-FASTER interventional clinical trial.  Focusing on point-of-care technology within an Accelerated Diagnostic algorithm (0-2 h), it discusses the clinical utilization of this algorithm conducted at Christchurch Hospital in New Zealand and highlights its impact on reducinTo enhance care delivery in emergency departments (EDs) through faster risk-stratification methods, this study showcases initial findings from the ICare-FASTER interventional clinical trial.  Focusing on point-of-care technology within an Accelerated Diagnostic algorithm (0-2 h), it discusses the clinical utilization of this algorithm conducted at Christchurch Hospital in New Zealand and highlights its impact on reducing the overall length of stay for patients.

Which rapid algorithm/s with high-sensitive troponin assays do ESC guidelines recommend to rule-in and rule-out NSTEMI?